Results 181 to 190 of about 131,254 (306)

A Systematic Review on Disease‐Modifying Therapies in Parkinsonian Disorders

Clinical Pharmacology &Therapeutics, EarlyView.
Parkinsonian disorders, including Parkinson's disease, Lewy body dementia, multiple system atrophy, and progressive supranuclear palsy, are progressive neurodegenerative conditions with no treatment options to slow disease progression. This systematic review provides an overview of evidence of disease‐modifying therapies that have been evaluated in ...
Pepijn P.N.M. Eijsvogel, Lars M.G. Smits, Philip H.C. Kremer, Geert Jan Groeneveld   +3 more
wiley   +1 more source

Editorial: Novel chimeric antigen receptor (CAR) designs in engineering NK cells for cancer. [PDF]

Front Immunol
Chan WK.
europepmc   +1 more source

Using electroporation to determine function of a chimeric antigen receptor in T cell and macrophage cell lines

, 2013
Using electroporation to determine function of a chimeric antigen receptor in T cell and macrophage cell ...
CSM Yong (14473233), PK Darcy (14473242), MH Kershaw (14473245), CPM Duong (15789299), LB John (15789287), C Devaud (13423683)   +5 more
core  

Flow cytometry‐based monitoring of chimeric antigen receptor (CAR) T cells: Reagent selection, assay design, and clinical utility

Cytometry Part B: Clinical Cytometry, EarlyView.
Abstract Accurate quantification of chimeric antigen receptor (CAR) T cells is essential for monitoring post‐infusion CART expansion and persistence and for real‐time clinical decision‐making. Multiparameter flow cytometry (MFC) enables rapid, live‐cell detection with absolute quantification and concurrent immunophenotypic characterization. This review
Jianhua Ling, Wei Wang, Sa A. Wang
wiley   +1 more source

Targeting amyloid-β pathology by chimeric antigen receptor astrocyte (CAR-A) therapy. [PDF]

Science
Chen Y, Liu Y, Nguyen K, Wu J, Song S, Lin K, Rodrigues PF, Du S, Zhou C, Xiong K, Bosch M, Lin PB, Khantakova D, Wu S, Wu M, Yuede C, Holtzman DM, Colonna M.   +17 more
europepmc   +1 more source

RORγt‐APCs: The New Masters of Oral Tolerance

Barrier Immunity, EarlyView.
ABSTRACT Oral tolerance is defined by the hypo‐responsiveness of our body to fed antigens, and its failure can lead to immune‐mediated diseases, such as allergy, chronic inflammation and autoimmune diseases. Decades of research have demonstrated that antigen‐presenting cells (APCs) promote oral tolerance by inducing regulatory T cells (Tregs) and/or ...
Thierry Gauthier, WanJun Chen
wiley   +1 more source

The Pleiotropic Roles of Cytokines in Chimeric Antigen Receptor T-cell Therapy. [PDF]

Cancer Immunol Res
Stewart CM, Siegler EL, Kenderian SS.
europepmc   +1 more source

CHIMERIC ANTIGEN RECEPTOR T CELLS: PAST, PRESENT, AND FUTURE

Chimeric antigen receptor T (CAR T) therapy, a type of anticancer cellular immunotherapy, is emerging expeditiously. Primarily reported in 1987, the concept of a chimeric T-cell receptor (TCR), which combines antibody-derived variable regions with TCR ...
BM, NAGARAJ, DP, SHRUTHI
core  

Novel Organelle‐Based Intracellular Immunity With Mechanistic and Therapeutic Implications

Barrier Immunity, EarlyView.
A conceptual framework illustrating how PAMPs/DAMPs initiate barrier, innate, adaptive, and intracellular immune responses, with organelle‐based intracellular immunity serving as a central integrator linking metabolism, inflammatory signaling, and therapeutic interventions to restore immune homeostasis.
Keman Xu, Shih‐Yu Hung, Fatma Saaoud, Ying Shao, Yifan Lu, Juanjuan Liu, Bo Yuan, Haiyan Xiang, Hong Wang, Xiaofeng Yang   +9 more
wiley   +1 more source

Auto-inducible expression of chimeric antigen receptor T cells using the NR4A1 promoter. [PDF]

Immunol Cell Biol
Smith-Bell SW, Halpin JC, Darcy PK, Liyanage T, Dobson LJ, McLellan AD.   +5 more
europepmc   +1 more source